Information

全研究実績

2014

基礎
283

Ito G, Fujimoto T, Kamikawaji S, Kuwahara T, Iwatsubo T: Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. PLoS One 9:e97988, 2014

基礎
282

Kanatsu K, Morohashi Y, Suzuki M, Kuroda H, Watanabe T, Tomita T, Iwatsubo T: Decreased CALM expression reduces Abeta42 to total Abeta ratio through clathrin-mediated endocytosis of gamma-secretase. Nat Commun 5:3386, 2014

基礎
281

Tanaka T, Wakabayashi T, Oizumi H, Nishio S, Sato T, Harada A, Fujii D, Matsuo Y, Hashimoto T, Iwatsubo T: CLAC-P/collagen type XXV is required for the intramuscular innervation of motoneurons during neuromuscular development. J Neurosci 34:1370-1379, 2014

基礎
279

Ohki Y, Shimada N, Tominaga A, Osawa S, Higo T, Yokoshima S, Fukuyama T, Tomita T, Iwatsubo T: Binding of longer Abeta to transmembrane domain 1 of presenilin 1 impacts on Abeta42 generation. Mol Neurodegener 9:7, 2014

基礎
284

Yonezawa H, Nishiyama Y, Takeo K, Iwatsubo T, Tomita T, Yokoshima S, Fukuyama T: New photocleavable linker: alpha-thioacetophenone-type linker. Bioorg Med Chem Lett 24:2831-2833, 2014

基礎
277

Li Y, Lu S H, Tsai C J, Bohm C, Qamar S, Dodd R B, Meadows W, Jeon A, McLeod A, Chen F, Arimon M, Berezovska O, Hyman B T, Tomita T, Iwatsubo T, Johnson C M, Farrer L A, Schmitt-Ulms G, Fraser P E, St George-Hyslop P H: Structural interactions between inhibitor and substrate docking sites give insight into mechanisms of human PS1 complexes. Structure 22:125-135, 2014

基礎
285

Takeo K, Tanimura S, Shinoda T, Osawa S, Zahariev I K, Takegami N, Ishizuka-Katsura Y, Shinya N, Takagi-Niidome S, Tominaga A, Ohsawa N, Kimura-Someya T, Shirouzu M, Yokoshima S, Yokoyama S, Fukuyama T, Tomita T, Iwatsubo T: Allosteric regulation of gamma-secretase activity by a phenylimidazole-type gamma-secretase modulator. Proc Natl Acad Sci U S A 111:10544-10549, 2014

基礎
280

Doody R S, Thomas R G, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen P S, Siemers E, Liu-Seifert H, Mohs R: Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311-321, 2014

基礎
286

Villemagne V L, Kim S Y, Rowe C C, Iwatsubo T: Imago Mundi, Imago AD, Imago ADNI. Alzheimers Res Ther 6:62, 2014

基礎
278

Taniguchi A, Sasaki D, Shiohara A, Iwatsubo T, Tomita T, Sohma Y, Kanai M: Attenuation of the aggregation and neurotoxicity of amyloid-beta peptides by catalytic photooxygenation. Angew Chem Int Ed Engl 53:1382-1385, 2014

PATE TOP